Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04381169
Other study ID # CEIM HGUA 2019/003
Secondary ID PI19/016282019-0
Status Terminated
Phase Phase 3
First received
Last updated
Start date May 28, 2020
Est. completion date September 25, 2021

Study information

Verified date March 2022
Source Hospital General Universitario de Alicante
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

WATERFALL is an investigator-initiated international multicenter open-label randomized clinical trial comparing aggressive versus moderate fluid resuscitation in acute pancreatitis. The main outcome variable will be the proportion of patients with moderate-to-severe AP. Aggressive fluid resuscitation will consist in Lactated Ringer Solution (LR) 20 ml/kg bolus (administered over 2 hours) followed by LR 3 ml/kg/h and moderate a LR bolus 10 ml/kg in case of hypovolemia or no bolus in patients with normal volemia, followed by LR 1.5 ml/kg/h. The patients will be assessed at 3 (±1), 12 (±4), 24 (±4), 48 (±4) and 72 (±4) hours from recruitment, and fluid resuscitation will be adjusted to the patient´s clinical and analytical status according to a protocol. Subgroup analysis will include patients with systemic inflammatory response syndrome (SIRS) at admission, with persistent (>48h) SIRS and with hypovolemia at admission. Based on available data (Sternby et al, Ann Surg 2019) we expect a 35% incidence of moderate to severe AP in the moderate arm. Sample sizes of 372 per arm of treatment (744 patients) achieve 80% power to detect a difference of 10% between the treatment arms at a significance level (alpha) of 0.05 using a two-sided z-testNA, assuming a 10% dropout. These results assume that 3 sequential tests are made using the O'Brien-Fleming spending function to determine the test boundaries. All analyses will be performed on an intention-to-treat basis. The trial could be stop early for efficacy (primary end-point) if the observed two-sided P value is <0.0002 at the first interim analysis (after 1/3 of patients have been enrolled) or is <0.012 at second interim analysis (after 2/3 of patients have been enrolled), favoring aggressive fluid resuscitation. At final analysis, the hypothesis that the incidence of moderate-to-severe pancreatitis is similar in the two treatment arms will be rejected if p<0.046


Recruitment information / eligibility

Status Terminated
Enrollment 249
Est. completion date September 25, 2021
Est. primary completion date September 25, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients age greater or equal to 18 presenting to one of the collaborating centers - Diagnosis of acute pancreatitis according to the revised Atlanta classification which requires 2 of the following 3 criteria: A) Typical abdominal pain; B) Increase in serum amylase or lipase levels higher than 3 times the upper limit of normality; and C) Signs of AP in imaging. Exclusion Criteria: - Uncontrolled arterial hypertension (systolic blood pressure >180 and/or diastolic blood pressure 100 mmHg); - New York Heart Association Class II hear failure (slight limitation of physical activity; fatigue, palpitations or dyspnea with ordinal physical activity) or worse, or ejection fraction<50% in the last echocardiography; - Decompensated cirrhosis (Child's Class B or C); - Hyper or hyponatremia (<135 or >145 mEq/l); - Hyperkalemia (>5 mEq/l); - Hypercalcemia (albumin or protein-corrected calcium>10.5 mg/dl); - Chronic kidney failure (basal glomerular filtration rate <60 mL/min/1.73m2); - Clinical signs or symptoms of volume overload or heart failure at recruitment (dyspnea, peripheral edema, pulmonary rales, or evident increased jugular ingurgitation at 45º); - Shock or respiratory failure according to the revised Atlanta classification at recruitment (non-fluid responding systolic blood pressure< 90 mmHg, PaO2/FIO2=300 mmHg); - Time from pain onset to arrival to emergency room >24h; - Time from confirmation of pancreatitis to randomization >8h; - Severe comorbidity associated with an estimated life expectancy <1 year; - Confirmed chronic pancreatitis (in case of recurrent alcoholic pancreatitis a recent (<6 months) CT scan/MRI or endoscopic ultrasound is needed to rule out chronic pancreatitis

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lactated Ringer Solution
Comparison of aggressive versus moderate Lactated Ringer-based fluid resuscitation

Locations

Country Name City State
Spain Alicante Alicante
Spain Hospital General Universitario de Alicante Alicante

Sponsors (4)

Lead Sponsor Collaborator
Enrique de-Madaria Asociación Española de Gastroenterología, Asociación Española de Pancreatología, Instituto de Salud Carlos III

Country where clinical trial is conducted

Spain, 

References & Publications (1)

Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013 Jan;62(1):102-11. doi: 10.1136/gutjnl-2012-302779. Epub 2012 Oct 25. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Moderate-to-severe acute pancreatitis Moderate or severe category of the Revised Atlanta Classification (Banks et al, Gut 2013) From admission to discharge, up to 24 weeks
Secondary Death and/or persistent organ failure and/or infection of pancreatic necrosis Analyzed as a composite endpoint and each of its components, includes in-hospital mortality, persistent organ failure (according to the revised Atlanta classification, Banks et al, Gut 2013) or infection of pancreatic necrosis From admission to discharge, up to 24 weeks
Secondary Fluid overload Fluid overload is defined by the absence of Acute Respiratory Distress Syndrome and at least 2 of the following 3 criteria (based on Sharma et al, Lancet Diabetes Endocrinol 2016, with modifications):
Criteria 1. Hemodynamic-imaging evidence (=1):
Non-invasive diagnostic evidence of heart failure (i.e., echocardiographic, cardiac MRI)
Radiographic evidence of pulmonary congestion
Invasive cardiac catheterization suggesting evidence of heart failure (i.e., pulmonary capillary wedge pressure [or left ventricular end-diastolic pressure] >18 mm Hg, right arterial pressure [or central venous pressure] >12 mm Hg, or cardiac index < 2·2 L/min per m2)
Criteria 2. Heart failure symptoms (1):
- Dyspnea
Criteria 3. Heart failure signs (=1):
Peripheral edema
Pulmonary rales or crackles, or crepitation
Increased jugular venous pressure, hepatojugular reflux, or both
From admission to discharge, up to 24 weeks
Secondary Shock Systolic blood pressure <90 mmHg after fluid resuscitation From admission to discharge, up to 24 weeks
Secondary Respiratory failure PaO2/FIO2<300 From admission to discharge, up to 24 weeks
Secondary Kidney failure Creatinine >1.9 mg/dL From admission to discharge, up to 24 weeks
Secondary Local complications (acute peripancreatic fluid collections/ pancreatic necrosis/peripancreatic necrosis) As described on the revised Atlanta classification, Banks et al, Gut 2013 From admission to discharge, up to 24 weeks
Secondary Length of hospital stay From admission to discharge, up to 24 weeks
Secondary Intensive care unit stay Need for intensive care unit (ICU) admission, and days admitted in the ICU From admission to discharge, up to 24 weeks
Secondary Need for invasive treatment Endoscopic, percutaneous or surgical treatment of acute pancreatitis complications From admission to discharge, up to 24 weeks
Secondary Need for nutritional support Need for enteral/parenteral feeding From admission to discharge, up to 24 weeks
Secondary PAN-PROMISE scale Score on an acute pancreatitis Patient-Reported Outcome Measurement At 12, 24, 48 and 72 hours
Secondary C-reactive protein Blood levels of C-reactive protein 48 and 72 hours
Secondary Systemic inflammatory response syndrome (SIRS) SIRS at the different checkpoints. Presence of persistent (>48h) SIRS Baseline, 12, 24, 48 and 72 hours
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05410795 - Establishment and Verification of Pancreatic Volume Formula Based on Imaging
Recruiting NCT04195347 - Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase Phase 1/Phase 2
Completed NCT04735055 - Artificial Intelligence Prediction for the Severity of Acute Pancreatitis
Completed NCT02928718 - The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations
Terminated NCT02885441 - Treatment of Acute Pancreatitis With Ketorolac Phase 4
Completed NCT02563080 - Pancreatic Exocrine Insufficiency in Acute Pancreatitis
Recruiting NCT01626911 - Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis N/A
Completed NCT01507766 - The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis Phase 4
Completed NCT04901949 - The Course of Acute Pancreatitis in Patients With Different BMI Groups
Recruiting NCT04814693 - Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis N/A
Completed NCT02743364 - Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis Phase 2
Recruiting NCT05281458 - Early Versus Standard Endoscopic Interventions for Peripancreatic Fluid Collections N/A
Not yet recruiting NCT04990336 - Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis N/A
Not yet recruiting NCT03259880 - Searching the Best Prognostic Factor in Out Come Evaluation in Patients With Acute Pancreatitis Admitted at Assiut University Hospitals N/A
Completed NCT02543658 - Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension Phase 2
Recruiting NCT06023771 - Invasive Intervention of Local Complications of Acute Pancreatitis
Not yet recruiting NCT05501314 - Remote Home Monitoring Acute Pancreatitis N/A
Completed NCT02897206 - Imipenem Prophylaxis in Patients With Acute Pancreatitis Phase 4
Recruiting NCT03634787 - Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis
Active, not recruiting NCT04989166 - Effect of Nano-curcumin Supplementation in Acute Pancreatitis N/A